Global (English)
The trial, led by Dr. Joost Daemen (cardiologist at the Thoraxcenter at the Erasmus University Medical Center, Rotterdam, The Netherlands), is an investigator initiated international, multi-center randomized, non-inferiority trial. 500 patients are enrolled by hospitals with great expertise in coronary physiology at 25 sites across Europe in The Netherlands, Germany, Spain, Ireland, United Kingdom, Italy, and France. A total of 35 sites will be recruited with the final aim to include 2,228 patients by the end of the year.
CAAS vFFR (Pie Medical Imaging, Maastricht, The Netherlands) is an angio-based FFR software suite to enable physiological assessment of intermediate coronary stenosis without the need of a pressure wire and adenosine. The vFFR value can be calculated with solely two angiographic projections and the aortic root pressure. This vFFR has a high correlation and diagnostic accuracy compared with wire based invasive FFR and NHPR measurements and the vFFR results are proven to be highly reproducible.
“The FAST III trial, together with several other studies currently being performed with CAAS vFFR, will increase the scientific body of evidence showing that the CAAS vFFR software is an excellent alternative to invasive wire-based physiological measurements” said Rene Guillaume, Managing Director PMI.
The trial is funded by research grants from Pie Medical Imaging (Maastricht, the Netherlands) and Siemens Healthineers (Erlangen, Germany). The study is sponsored by ECRI (European Cardiovascular Research Institute, Rotterdam-the Netherlands). Cardialysis (Rotterdam, The Netherlands) is responsible for trial services including trials management and Core Laboratory activities.
